NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) („NeuroSense“), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients‘ blood to quantify drug-induced neuronal plasticity in vitro.
Distinguished by its innovative approach, NeuroSense’s PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (A?), PrimeC adopts a multi-targeted strategy, concurrently addressing A? aggregation, TDP-43, and other key disease-related pathologies.
This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes.
